Tyra Biosciences, Inc.
TYRA · Pharmaceutical Preparations · 59.5M shares · +61%/yr ↑ dilution · EDGAR filings ↗
Reference price $36.97 · est. market cap ~$2.2B — last insider sale, 2026-03-25 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical/early-stage biotech — precision-oncology clinical, very cash-rich.
Strengths
- Liquidity — current ratio 14.7 (90th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Cash burnNegative free cash flow (-95.3M)
- Exec changeRecent 8-K item 5.02 8-K ↗
- Chronic dilutionShare count +61%/yr over 3y (dilution, book value/share -76%)
- Insider sellingInsider selling — 5 open-market sale(s) by 2 insider(s) (cluster of 2 insiders, ~$1M, last 6mo) Form 4 ↗
- Notable holderHeld by 4 notable fund(s): FMR LLC, STATE STREET CORP, GOLDMAN SACHS GROUP INC +1 more (as of 2026-03-31)
- Trial readout soonUpcoming trial readout ~2026-11 — PHASE1/PHASE2 · Locally Advanced Urothelial Carcinoma
Key metrics
Return on equity
-46.3%
Return on assets
-42.4%
Current ratio
14.7×
Free cash flow
-$95M
EBITDA
-$132M
Tangible book value
$259M
Cash & investments
$77M
Cash runway
3q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-05 | Fuhrman Alan | Grant | 20K | — |
| 2026-05-05 | Warner Douglas J | Grant | 25K | — |
| 2026-05-05 | Harris Todd | Grant | 79K | — |
| 2026-05-05 | Ashar Bhavesh | Grant | 15K | — |
| 2026-05-05 | Rueb Yuliya | Grant | 8.3K | — |
| 2026-03-26 | KAPLAN GILLA | Option exercise | 53K | $2.25 |
| 2026-03-26 | KAPLAN GILLA | Disposition | 53K | $37.75 |
| 2026-03-25 | KAPLAN GILLA | Option exercise | 14K | $2.25 |
| 2026-03-25 | KAPLAN GILLA | Sell | 14K | $36.97 |
| 2026-03-13 | Harris Todd | Grant | 1.5K | $9.13 |
| 2026-03-13 | Fuhrman Alan | Grant | 1.4K | $9.13 |
| 2026-02-12 | Bensen Daniel | Sell | 2.1K | $31.50 |
| 2026-02-12 | Bensen Daniel | Sell | 5.9K | $33.37 |
| 2026-01-12 | Bensen Daniel | Sell | 7.0K | $28.44 |
| 2026-01-12 | Bensen Daniel | Sell | 1.0K | $29.08 |
| 2025-12-19 | MORE ROBERT J | Sell | 10K | $25.00 |
| 2025-12-12 | Bensen Daniel | Sell | 8.0K | $22.64 |
| 2025-11-21 | MORE ROBERT J | Sell | 247K | $20.25 |
| 2025-11-19 | Bensen Daniel | Sell | 50K | $16.32 |
| 2025-11-18 | Bensen Daniel | Sell | 76K | $16.07 |
| 2025-11-17 | Bensen Daniel | Sell | 1.5K | $17.07 |
| 2025-11-17 | Bensen Daniel | Sell | 19K | $16.11 |
| 2025-11-14 | Bensen Daniel | Sell | 110K | $16.02 |
| 2025-11-13 | Bensen Daniel | Sell | 1.1K | $16.00 |
| 2025-09-15 | Fuhrman Alan | Grant | 701 | $9.13 |
| 2025-06-18 | KAPLAN GILLA | Sell | 9.6K | $9.78 |
| 2025-06-17 | KAPLAN GILLA | Sell | 10 | $10.35 |
| 2025-06-16 | RA CAPITAL MANAGEMENT, L.P. | Buy | 12K | $10.13 |
| 2025-06-16 | KAPLAN GILLA | Sell | 6.8K | $10.38 |
| 2025-06-13 | RA CAPITAL MANAGEMENT, L.P. | Buy | 120K | $10.20 |
| 2025-06-13 | KAPLAN GILLA | Sell | 15K | $10.31 |
| 2025-06-12 | RA CAPITAL MANAGEMENT, L.P. | Buy | 31K | $10.20 |
| 2025-06-12 | KAPLAN GILLA | Sell | 30K | $10.31 |
| 2025-06-09 | RA CAPITAL MANAGEMENT, L.P. | Buy | 187K | $10.19 |
| 2025-06-05 | RA CAPITAL MANAGEMENT, L.P. | Buy | 213K | $10.04 |
| 2025-06-04 | RA CAPITAL MANAGEMENT, L.P. | Buy | 998K | $9.63 |
| 2025-03-14 | Harris Todd | Grant | 1.2K | $9.78 |
| 2025-03-14 | Fuhrman Alan | Grant | 1.2K | $9.78 |
| 2025-02-05 | Kjellson Nina S | Sell | 1.9K | $13.76 |
| 2025-02-05 | Kjellson Nina S | Sell | 3.5K | $13.76 |
| 2025-01-23 | Kjellson Nina S | Sell | 4.8K | $16.26 |
| 2025-01-21 | Kjellson Nina S | Sell | 4.0K | $16.36 |
| 2025-01-17 | Kjellson Nina S | Sell | 13K | $16.40 |
| 2025-01-17 | Kjellson Nina S | Sell | 461 | $16.40 |
| 2025-01-16 | Kjellson Nina S | Sell | 835 | $16.29 |
| 2025-01-16 | Kjellson Nina S | Sell | 6.9K | $16.29 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07265947 ↗ | Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma Low Grade Upper Tract Urothelial Carcinoma | PHASE2 | Recruiting | 2030-10-01 |
| NCT06842355 ↗ | A Study of TYRA-300 in Children With Achondroplasia: BEACH301 Achondroplasia | PHASE2 | Recruiting | 2030-01-01 |
| NCT06995677 ↗ | Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer Low-grade NMIBC, FGFR Gene Amplification | PHASE2 | Recruiting | 2028-02-01 |
| NCT06915753 ↗ | Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations Metastatic Hepatocellular Carcinoma, Solid Tumors | PHASE1 | Recruiting | 2028-01-01 |
| NCT05544552 ↗ | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | PHASE1/PHASE2 | Active Not Recruiting | 2026-11-01 |
| NCT06160752 ↗ | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | PHASE1 | Recruiting | 2026-09-01 |
| NCT06006702 ↗ | A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants Healthy | PHASE1 | Active Not Recruiting | 2025-05-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-02 | 2026-05-28 | 0001193125-26-253435 ↗ |
| 8-K | 2026-05-13 | 2026-05-13 | 0001193125-26-220638 ↗ |
| 10-Q | 2026-05-13 | 2026-03-31 | 0001193125-26-220645 ↗ |
| 8-K | 2026-04-17 | 2026-04-16 | 0001193125-26-160347 ↗ |
| 8-K | 2026-04-02 | 2026-04-01 | 0001193125-26-140027 ↗ |
| 8-K | 2026-03-04 | 2026-03-04 | 0001193125-26-091880 ↗ |
| 10-K | 2026-03-02 | 2025-12-31 | 0001193125-26-085490 ↗ |
| 8-K | 2026-03-02 | 2026-03-02 | 0001193125-26-085399 ↗ |
| 8-K | 2025-12-01 | 2025-11-25 | 0001193125-25-303162 ↗ |
| 10-Q | 2025-11-05 | 2025-09-30 | 0001193125-25-266967 ↗ |
| 8-K | 2025-11-05 | 2025-11-05 | 0001193125-25-266916 ↗ |
| 8-K | 2025-08-22 | 2025-08-21 | 0001193125-25-185553 ↗ |